Ashton, NJ;
Hye, A;
Rajkumar, AP;
Leuzy, A;
Snowden, S;
Suarez-Calvet, M;
Karikari, TK;
... Aarsland, D; + view all
(2020)
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
Nature Reviews Neurology
, 16
(5)
pp. 265-284.
10.1038/s41582-020-0348-0.
Preview |
Text
Zetterberg_An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders_AAM.pdf - Accepted Version Download (627kB) | Preview |
Abstract
Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-β, tau, phosphorylated tau and neurofilament light chain, are likely to be relevant to other neurodegenerative disorders that involve similar pathological processes and could also be useful for the differential diagnosis of clinical symptoms. This Review outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and gives an overview of the current status of blood-based biomarkers for these disorders.
Archive Staff Only
 |
View Item |
